CGP 39551

Cat. No.:HY-107703CAS No.:127910-32-1Molecular Formula:C ₈ H ₁₆ NO ₅ PMolecular Weight:237.19Target:iGluRPathway:Membrane Transporter/Ion Channel; Neuronal SignalingStorage:Please store the product under the recommended conditions in the Certificate of Analysis.	
---	--

BIOLOGICAL ACTIVITY	
Description	CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity ^[1] . CGP 39551 shows measurable inhibitory activity at both L-[³ H]-glutamate (K _i =8.4 μM) ^[2] .
In Vitro	CGP 39551 inhibits the binding of the selective NMDA receptor antagonist, [³ H]-CPP to rat brain postsynaptic densities (PSDs) with a K _i of 310 nM ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CGP 39551 exhibits maximal electroshock-induced seizures in mice with the ED ₅₀ of 4 mg/kg (p.o.) ^[2] . Following chronic neonatal treatment with CGP 39551, adult rats show increased behavioral responses to the D2 dopamine receptor stimulation ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. G E Fagg, et al. CGP 37849 and CGP 39551: novel competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity. Prog Clin Biol Res. 1990;361:421-7.

[2]. G E Fagg, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol. 1990 Apr;99(4):791-7.

[3]. R Dall'Olio, et al. Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat. Neuroscience. 1994 Nov;63(2):451-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

98 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

MCE ®

Product Data Sheet